Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL - Sehn, L H; Kamdar, M; Herrera, A F (J Clin Oncol, 2018)
. doi:10.1200/JCO.2018.36.15_suppl.7507